Become A Member

Uzma Raza¹, Aziza Khanam³, Ali Iftikhar⁴, Sidra Rizwan⁵, Tooba Mahmud Gauhar² and Amel Hanan Zehra⁶

ABSTRACT

Objective: To assess the survival time in breast cancer patient who undergo adjuvant radiotherapy and adjuvant hormonal therapy.

Study Design: Cross sectional observation al study.

Place and Duration of Study: This study was conducted at the Al-Tibri Medical College with collaboration of Liaquat National Hospital Karachi from May 2018 to September 2022.

Materials and Methods: The study includes 174 breast cancer female patients having tumor grade II and III from different tumor grades. The patient’s physical examination hematological and biochemical evaluations were performed and were treated on the basis of tumor grade size, node involvement and hormone receptor status. The patients were subjected to surgery and chemotherapy with adjuvant therapy (Radiotherapy or Hormonal Therapy). The patients were followed up to five years. The disease-free survival time was noted from the date of diagnosis and initial treatment to the date of re-appearance of cancer at some other site.

Results: The relapse free survival time of the patients taking adjuvant hormonal therapy is higher than the patients having adjuvant radiotherapy.

Conclusion: The adjuvant hormonal therapy is the better option of treatment in tumor grade II and grade III patients.

Key Words: Breast cancer, Adjuvant radiotherapy and chemotherapy, Relapse free survival time.

Citation of article: Raza U, Khanam A, Iftikhar A, Rizwan S, Gauhar TM, Zehra AH. Relapse Free Survival Time of Breast Cancer Patients Treated With Adjuvant Radiotherapy and Hormone Therapy. Med Forum 2023;34(5):101-104.